深入揭秘

随着数字代币交易日益活跃，一个名为“中继市场”的灰色产业链悄然成型。该市场专门为代币转售者提供自动化工具和匿名交易通道，使大量被盗或非法获取的代币能够快速变现。调查发现，这些中继服务通常部署在海外服务器上，利用加密通信和智能合约绕过监管，对合法用户资产安全构成严重威胁。安全专家警告，此类市场不仅助长了网络欺诈和洗钱活动，还可能被用于资助其他非法行为。目前，多家交易所已加强风控措施，但中继市场的分布式特性使得追踪和取缔极为困难。 #代币 #欺诈 #中继市场 #网络安全 #加密货币 #数字资产 #黑灰产

Zuzai

作者提出新词“zuzai”以指代不含人工智能的事物，类似“纯素”一词相对动物产品那样。zuzai 是一个递归缩写，全小写，发音如“zoo's eye”。作者认为，随着AI生成内容泛滥，人们需要一个正面、生动的词汇来描述非AI创作，而非含糊的“无AI”或“非AI”。该词可用于描述作品（如文章、图像）、工作模式（如zuzai模式）或环境（如zuzai测试环境）。虽为生造词，但作者以“纯素”一词由普通人首创并普及为例，认为zuzai有潜力被广泛接受。语言学专家朋友对此持保留态度，认为新词流行受“无形之手”支配，很难通过提案推动。 #Zuzai #无AI #新造词 #语言 #科技 #AI #纯素 #递归缩写 #人造词

LLM法官

在一篇关于生成式AI质量控制的深度分析中，作者以钻石销售场景为例，揭示了语言模型“流畅但可能不真实”的核心问题。AI助手在解释钻石时，可能依据真实数据（如SI1净度等级）编造出“凭肉眼无法看见瑕疵”的错误结论——因为SI1等级是在10倍放大镜下评定的，并非肉眼可见度的标准。这种流畅的谎言难以通过事前规则防范。为此，作者提出一套三层质量控制机制：第一层通过代码在管道中阻止模型提出无法从证据中回答的问题；第二层和第三层则构建一个独立的LLM法官，逐条核对模型生成的每个声明与提供的证据（如证书、价格等）是否一致，并给出可量化的判决。这套系统使得针对同一事实的争论不再存在，因为法官的裁决是客观可验证的。 #AI #大模型 #LLM #质量评估 #生成式AI #钻石 #科技 #人工智能

类型系统在AI时代重塑代码审查，聚焦设计意图

随着AI代理和大型语言模型改变编程模式，代码审查面临新挑战。一位技术专家近日撰文指出，类型系统凭借其精简描述系统行为的能力，正成为应对LLM生成代码的关键工具。在代码量激增且由AI生成、缺乏个人特色的背景下，直接审查类型可快速把握设计边界，避免陷入实现细节，将焦点从冗余的逐行阅读转向人的意图和架构决策。文章认为，相比AI生成的摘要（常误导或遗漏关键信息）和提示词审查（隐私与准确性均存忧），类型系统提供了更高效可靠的短路径。作者呼吁工程组织更广泛深入地采用类型，以在AI时代保持代码的可维护性和审查质量。 #类型系统 #AI #代码审查 #编程 #软件开发 #大模型 #技术观点 #LLM #工程效率

Telegram必备的搜索引擎，极搜JISOU帮你精准找到，想要的群组、频道、视频、音乐

👉 t.me/jisou2?start=a_8247614025

ents treated with DT120. From Definium Therapeutics’ Corporate Presentation , page 36: So what’s the big deal? DT120 could potentially treat major depressive disorder (MDD) and generalized anxiety disorder (GAD). So far they got one jaw-dropping phase 3 trial readout for MDD already out , two more phase 3 trial readouts for GAD to come in early Q3 2026, and in late Q3 2026 (worth mentioning: Definium, named MindMed at the time, was awarded Breakthrough Therapy Designation by the FDA because of how groundbreaking DT120 proved to be for GAD in phase 2), not to mention a phase 3 trial for Post-Traumatic Stress Disorder (PTSD) starting next year. You’re confused? Here’s a quick snapshot from the Corporate Presentation , page 8, with all Definium’s clinical trials + upcoming catalysts for DT120. Yeah, yeah, it all sounds very complicated, doesn’t it? But it isn’t . In layman terms, psychedelics like LSD have been relegated to the fringes of medical science for ages. And not even the fringes, beyond the fringes: they were basically the scourge of the earth, or, as three-letter agencies use to say, a Schedule I drug, on par with heroin. Some years ago Definium Therapeutics and other companies kickstarted a new age of psychedelic medicine — this time based on clinical trials under the guidance of the FDA. And what they discovered was massive. DT120, if all these trial readouts go well — which, of course, they might not, but let’s entertain the possibility everything’s peachy for a moment — is nothing short of a miracle drug . A single, best-in-class, almost-one-and-done formulation with a potential total addressable market (TAM) of 200 billion dollars. And I’m not fabricating numbers, it’s all in black and white on page 36 of Definium’s Corporate Presentation . I promised you math, didn’t I? So here it is. $2 billion revenue opportunity for every 1% of market penetration. Let’s assume trials go well. How big of a market share will DT120 acquire by, say, 2030? Let’s be pessimistic: let’s say 5% . 5% times 2 billion dollars per 1% penetration = 10 billion dollars. What’s the price to sales ratio for an average biotechnology company? According to the dataset of Aswath Damodaran , Professor of Finance at Stern School of Business of New York University, (dataset updated to January 2026), the answer is 7.31 . 7.31 times 10 billion dollars gives us a market cap of 73.1 billion dollars . You remember I told you there are currently 132.74M shares? Let’s be overly pessimistic and assume dilution up to 200M shares — mind you, more dilution is unlikely at this point, given the company has roughly over a billion dollars in cash, which should be enough to commercialize DT120 and get to profitability, but let’s crank caution up to eleven, just to be sure. So, what’s 73.1 billion dollars divided by 200M shares? It’s $365.50 per share. And I remind you, as of today, the company is worth 43.17 dollars a share. You read that right. Over 8x in 4 years , assuming that trial results confirm the greatness the company has got us accustomed to so far. And keep in mind, this is the base case, i.e., Definium gets to only 5% market penetration. Let’s be bold and consider, just for the sake of it, that there is no dilution and DT120 is truly a miracle drug, with a 20% market penetration. In such a case, the stock price would balloon to $2,202.80 per share. Which is 51.03x from today’s price. Many things could go wrong. In no particular order: There’s a non-zero chance